Core Viewpoint - A class action securities lawsuit has been filed against Applied Therapeutics, Inc. due to alleged securities fraud affecting investors between January 3, 2024, and December 2, 2024 [1] Group 1: Case Details - On November 27, 2024, Applied Therapeutics announced it received a Complete Response Letter (CRL) from the FDA for its New Drug Application (NDA) for govorestat, indicating deficiencies in the clinical application [2] - Following the CRL announcement, the stock price of Applied Therapeutics dropped from 8.57 on November 27, 2024, and further declined to 1.75 on December 2, 2024, marking a total decline of over 80% [2] - After disclosing a "warning letter" from the FDA regarding clinical trial issues on December 2, 2024, the stock price fell further to 1.38 on December 4, 2024, and $1.29 on December 5, 2024 [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until February 18, 2025, to request the Court to appoint them as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]
Class Action Filed Against Applied Therapeutics, Inc. (APLT) - February 18, 2025 Deadline to Join - Contact Levi & Korsinsky